Opaleye Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Opaleye Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-217,000	Closed	-$5.2M	–	41
2023 Q2	$5.2M	Buy	+217,000	New	+$4.82M	1.24%	22
2020 Q2	–	Sell	-1,500	Closed	-$63K	–	49
2020 Q1	$63K	Sell	1,500 -205,000	-99%	-$8.45M	0.02%	42
2019 Q4	$8.83M	Buy	206,500 +6,500	+3%	+$283K	1.73%	26
2019 Q3	$7.2M	Hold	200,000	–	–	2.6%	19
2019 Q2	$5.35M	Hold	200,000	–	–	1.63%	27
2019 Q1	$5.37M	Buy	200,000 +5,000	+3%	+$117K	1.49%	28
2018 Q4	$3.15M	Hold	195,000	–	–	1.18%	27
2018 Q3	$4.05M	Buy	+195,000	New	+$3.07M	1.03%	30

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Opaleye Management's ACAD Position: Q3 2023 in Review

Opaleye Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2023, closing a stake of 217,000 shares — an estimated $5.2M sold.

Opaleye Management first reported a position in ACAD in Q3 2018 and held it in 8 quarters. The position peaked at $8.83M in Q4 2019. 248 funds tracked by Wall St. Rank hold ACAD as of Q3 2023.

Opaleye Management reported no remaining Acadia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Opaleye Management sold 217,000 Acadia Pharmaceuticals shares in Q3 2023, an estimated $5.2M.
Opaleye Management first reported a position in Acadia Pharmaceuticals in Q3 2018 and held it in 8 quarters.
Opaleye Management's Acadia Pharmaceuticals position peaked at $8.83M in Q4 2019.
248 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2023.

Based on Opaleye Management's 13F filing for Q3 2023, filed 15 Nov 2023.